Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis
/in Esophageal Carcinoma, Hyperthermia, International Publications /von 2017-01-25 / J Clin Pharm Ther 2017 Apr;42(2):155-164Targeting immune checkpoints in malignant glioma
/in Checkpoint-Inhibitors, Glioblastoma, International Publications /von 2017-01-24 / Oncotarget 2017 Jan;8(4):7157-7174Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease
/in Brain Tumors in Children, International Publications, IOZK Veröffentlichungen /von 2017-01-21 / J Neurooncol 2017 04;132(2):255-266Regional hyperthermia combined with radiotherapy for esophageal squamous cell carcinoma with supraclavicular lymph node metastasis
/in Esophageal Carcinoma, Hyperthermia, International Publications /von 2017-01-17 / Oncotarget 2017 Jan;8(3):5339-5348Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
/in Dendritic Cells, International Publications, Prostate Cancer /von 2017-01-10 / Clin. Cancer Res. 2017 07;23(13):3352-3364Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-06 / Pharmacotherapy 2017 01;37(1):129-143Artikel:Deutsches Ärzteblatt: Präoperativer Impfstoff zeigt in Studie erste Wirkung
/in Externe Meldungen /von IOZKProgress in Vaccine Therapies for Breast Cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2017-01-01 / Adv Exp Med Biol 2017;1026:315-330Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-805
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution